What Does Minimal Residual Disease (MRD) Testing Actually Mean for Cancer Immunotherapy Patients?

What This Article Covers

When a scan shows "no evidence of disease" after cancer treatment, that doesn't mean every cancer cell is gone — it means none are visible by the tools being used. Minimal residual disease (MRD) testing goes a level deeper, using DNA sequencing and cell-surface protein analysis to hunt for cancer cells hiding below the resolution of a CT scan or a pathologist's microscope. In blood cancers especially — leukemia, lymphoma, and multiple myeloma — MRD status has become one of the most closely watched numbers in a patient's chart, increasingly used to guide treatment decisions after CAR-T therapy and other immunotherapies, and now moving toward a formal role in how the FDA evaluates new drugs. This article explains what MRD testing actually measures, how it's done, why regulators are rethinking its use, and — critically — what an MRD-negative result does and does not guarantee.

What Is Minimal Residual Disease?

Minimal residual disease refers to the small number of cancer cells that can remain in the body after treatment, even when standard imaging and lab tests suggest a patient has achieved "complete response." These residual cells are too few and too dispersed to be seen on a scan or under a microscope in a routine bone marrow smear — but they're detectable with more sensitive molecular and immunologic tools. The concept is most developed in blood cancers because bone marrow and blood samples are relatively easy to collect repeatedly and because leukemia, lymphoma, and myeloma cells often carry distinctive genetic "fingerprints" — unique DNA sequences from cell-receptor rearrangements — that let labs track a specific cancer clone with extraordinary precision.

How Is MRD Actually Tested?

There are three main approaches in current use, and they differ in sensitivity and what they actually detect. Multiparametric flow cytometry analyzes cells for abnormal patterns of surface proteins, sorting through tens of thousands of cells to flag ones that look leukemic or malignant; it's fast and widely available but generally less sensitive than newer methods. Next-generation sequencing (NGS)-based assays, such as Adaptive Biotechnologies' clonoSEQ — the first NGS-based MRD test to receive FDA marketing authorization, in September 2018 — sequence the DNA of a patient's cancer cells at diagnosis to identify a unique clonal marker, then screen follow-up bone marrow samples for that same sequence at extraordinarily low levels, down to roughly one cancer cell in a million. A third and newer approach uses circulating tumor DNA (ctDNA) drawn from a simple blood sample rather than bone marrow; in lymphoma, ctDNA-based methods can reach sensitivities in the range of one part in tens of thousands to, with some ultrasensitive techniques, closer to one in a million, making it possible to monitor for relapse non-invasively over time.

Why MRD Matters for Immunotherapy Patients

For patients undergoing CAR-T cell therapy, bispecific antibodies, or other immunotherapies for leukemia, lymphoma, or myeloma, MRD status has become one of the most meaningful readouts of how well treatment worked. Because these therapies are often given to patients who have already relapsed after multiple prior lines of treatment, oncologists want to know not just whether the cancer has responded, but how deeply — and MRD testing is currently the most sensitive tool available to answer that. Research presented at American Society of Hematology (ASH) meetings and published in journals like Blood Cancer Journal has repeatedly linked early MRD-negative status after CAR-T therapy in myeloma to better progression-free survival, reinforcing MRD's role as a prognostic signal clinicians use to gauge depth of response and, in some cases, to inform decisions about additional or maintenance therapy.

MRD as a Regulatory Endpoint: What's Changing

This is where the story becomes genuinely encouraging. Traditionally, new blood cancer drugs have needed to demonstrate improvements in progression-free or overall survival — endpoints that can take many years, sometimes close to a decade, to mature in clinical trials. MRD offers a much earlier readout, often available within nine to twelve months of treatment. On April 12, 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously, 12–0, that MRD could serve as an intermediate endpoint to support accelerated approval of new multiple myeloma therapies, after reviewing meta-analyses spanning 42 clinical trials and more than 21,000 patients. Then, in January 2026, the FDA released draft guidance formalizing expectations for how sponsors should use MRD negativity — combined with complete response — in myeloma trial design, describing MRD as an "intermediate clinical endpoint reasonably likely to predict benefit" rather than a fully validated surrogate. Similar work is underway in chronic lymphocytic leukemia (CLL), where researchers are developing MRD-based endpoints to potentially speed approvals there as well. If this framework holds up, it could meaningfully shorten the path from promising early data to patient access for new blood cancer immunotherapies — a real and important shift.

What MRD-Negative Does — and Doesn't — Mean

Here is the essential caveat, and it matters as much as the good news above: MRD-negative is not the same as cured. It means that with the specific test used, at its specific sensitivity threshold, no residual cancer cells could be detected — not that zero cancer cells remain. A patient can be MRD-negative and still relapse later, because cells can exist below a test's detection floor, because residual disease can be present in a location the sample didn't capture (a swollen lymph node versus the bone marrow sampled, for instance), or because dormant cells can re-emerge over time. The FDA's own draft guidance underscores this by requiring that overall survival still be evaluated as a companion endpoint — as the guidance frames it, "MRD does not replace OS. Instead, it sits alongside it." For this reason, major professional groups have generally cautioned that MRD results should inform prognosis and research, and increasingly clinical trial design, but should not yet be used alone to make individual treatment decisions outside of a structured clinical or trial context, until further guidelines mature.

Bottom Line

MRD testing represents one of the most sensitive tools oncology has for measuring how deeply a treatment has worked — capable of finding a single cancer cell among a million healthy ones — and it is reshaping both clinical monitoring and, increasingly, the regulatory pathway for new blood cancer immunotherapies. The FDA's 2024 advisory committee vote and its 2026 draft guidance genuinely could shorten the road to approval for promising new drugs. But "MRD-negative" is a statement about detection limits, not a guarantee of cure. Patients and families should treat it as an important, encouraging data point — one worth understanding and discussing with their care team — rather than a final verdict on whether cancer will return.